Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/65—Tetracyclines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C231/00—Preparation of carboxylic acid amides
  • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C231/00—Preparation of carboxylic acid amides
  • C07C231/22—Separation; Purification; Stabilisation; Use of additives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2603/00—Systems containing at least three condensed rings
  • C07C2603/02—Ortho- or ortho- and peri-condensed systems
  • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
  • C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
  • C07C2603/44—Naphthacenes; Hydrogenated naphthacenes
  • C07C2603/46—1,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines

Definitions

• the present invention relates to a manufacturing process for the preparation of tigecycline.
• Tigecycline is an antibiotic with a broad spectrum of antibacterial activity. Importantly tigecycline is effective against several resistant strains of bacteria. Tigecycline in a powder presentation is reconstituted by the addition of a compatible reconstitution diluent prior to intravenous infusion.
• the antibiotic tigecycline is a f-butylglycyl substituted naphthacenecarboxamide free base.
• Tigecycline is however difficult to manufacture because it is vulnerable to degradation including oxidative degradation from atmospheric oxygen and epimer formation.
• the present invention is directed to a manufacturing process for tigecycline by controlling epimer formation and oxidation degradation during the bulk manufacturing of the lyophilized powder presentation.
• controlling the temperature and oxygen level during the steps of the process are important features of the invention.
• Tigecycline is protected during the process by sparging with an inert gaseous medium comprising a nonreactive gas, such as nitrogen, and control of the temperature.
• An embodiment of the invention is to provide the manufacture of tigecycline with total degradants less than 0.9% by controlling the level of dissolved oxygen in conjunction with temperature control of the bulk aqueous solution.
• a further embodiment of the invention is to provide a manufacturing process for tigecycline as a reconstitutable powder having less than 0.9% total degradants and to further provide the tigecycline reconstitutable powder from solutions of water for injection (WFI) and tigecycline on at least an 80 L scale.
• WFI water for injection
• An embodiment of the invention is to provide a manufacturing process of tigecycline in WFI water at a concentration of about 10 to 50 mg/ml, preferably 20 mg/mL wherein the oxygen level in the water is less than 0.5 ppm by sparging said water with gaseous nitrogen and wherein said solution may be added to vials and the solution in said vials lyophilized to a reconstitutable powder.
• An additional embodiment of the invention is to provide a manufacturing process having a total manufacturing hold time for bulk solution of about 13 to about 24 hours for the production of tigecycline powder.
• a further embodiment of the invention is to provide tigecycline powder available for reconstitution prior to intravenous administration and having a shelf life of at least 18 months.
• An additional embodiment of the invention is to provide a manufacturing process wherein the WFI water is at a temperature of about 2°C to about 8 0 C.
• a further embodiment of the invention is to provide a maximum sterile holding time from the filling of the first vial to the start of lyophilization cycle of 6 hours.
• An embodiment of the invention is to provide a manufacturing process for the production of tigecycline as a reconstitutable powder having less than 0.9% total degradants comprising the steps: a. reducing and maintaining the oxygen level in WFI water to less than or equal to 0.5 ppm while maintaining the temperature at about 2°C to about 8 0 C; b. forming a solution of tigecycline in said water of step a at a concentration of about 10 to 50 mg/ml while maintaining said temperature and oxygen level; c. filling vials with said solution of step b; d. lyophilizing said solution of step c to form 25 mg to 150 mg of reconstitutable powder in a vial; and e. sealing said vial under nitrogen.
• a solution of tigecycline in step b of the above described process is at a concentration of about 20 mg/ml.
• Preferably 50 mg to 150 mg, more preferably 50 mg of reconstitutable powder is in the vial of step d of the above described process.
• the lyophilized and reconstituted tigecycline powder has been analyzed to have a reverse-phase HPLC elution profile substantially as shown in FIG. 1.
• FIG. 1 shows a typical chromatogram of the reverse-phase HPLC elution profile of tigecycline from the manufacturing process.
• FIG. 2 shows the steps of the tigecycline manufacturing process.
• the present invention provides a manufacturing process for tigecycline as a reconstitutable powder having less than 0.9% total degradants.
• the process to prepare the tigecycline reconstitutable powder may be provided from solutions of water for injection (WFI) and tigecycline on an 80 L scale or greater than an 80 L scale.
• WFI water for injection
• tigecycline on an 80 L scale or greater than an 80 L scale.
• total degradants we mesn compounds or products that are the result of degradation of tigecycline, including those formed due to oxidation of tigecycline (for example at the C-11 position forming a hydroxyl group or at the C-6 position followed by dehydration to form a 6-ene product), or those compounds or products formed due to secondary reactions (e.g.
• decarboxylation for example those products formed due to photo-induced reaction through hydrolysis and deamination at C-4 position.
• epimer Excluded from the definition are minocycline and 9-amino minocycline.
• the process provides a solution of tigecycline in WFI water at a concentration of about 10 to 50 mg/ml, preferably 20 mg/mL wherein the oxygen level in the water is less than 0.5 ppm by sparging said water with gaseous nitrogen and wherein said solution may be added to vials and the solution is said vials lyophilized to a reconstitutable powder.
• the invention provides a manufacturing process having a total manufacturing hold time for the bulk solution of about 13 to about 24 hours for the production of tigecycline powder available for reconstitution and further having a shelf life of at least 18 months.
• the invention provides a manufacturing process wherein the WFI water is held at a temperature of about 2°C to about 8°C and the water is further sparged with nitrogen so the oxygen level is below 5 ppm.
• the invention provides a manufacturing process for the production of tigecycline as a reconstitutable powder having less than 0.9% total degradants by first reducing and maintaining the oxygen level in WFI water to less than 0.5 ppm while maintaining the temperature at about 2°C to about 8°C before adding tigecycline and forming a solution at about 10 to 50 mg/ml while still maintaining the temperature and oxygen level.
• the solution of tigecycline in water can be added to vials and further lyophilized to a reconstitutable powder and the vial further sealed under nitrogen.
• the solution of tigecycline is at 20 mg/ml and the vial has about 50 mg of reconstitutable powder following lyophilization.
• dissolved oxygen content of the solution is more than 0.5 mg/L, continue filtered nitrogen sparging until a stable dissolved oxygen content measure is obtained.
• the contents of the sample vials are dissolved in diluent.
• the sample solution is diluted, if necessary, and chromatographed on a reversed phase column using gradient elution. Impurities are determined by comparing the impurity peak areas in the sample preparation chromatogram to the average area of tigecycline peaks in the standard preparation chromatograms obtained concomitantly.
• Detector - Ultraviolet spectrophotometry detector capable of operating at 248 nm with a sensitivity of about 0.5 absorbance units full scale.
• EDTA in 950 mL of water. Adjust pH to 6.4 with phosphoric acid. Add 50 mL of acetonitrile and mix well. Filter through a 0.45 ⁇ m pore size membrane filter, if necessary. Degas, if necessary.
• EDTA in 500 mL of water Adjust pH to 6.4 with phosphoric acid. Add 500 mL of acetonitrile and mix well. Filter through a 0.45 ⁇ m pore size membrane filter, if necessary. Degas, if necessary.
• Diluent Weigh 4.35 g of dibasic potassium phosphate and 0.50 g of sodium bisulfite into a one liter volumetric flask. Dissolve and dilute to volume with water. Adjust the pH of this solution to 8.0 with 1 N potassium hydroxide.
• EDTA Solution Weigh 3.7 g of sodium EDTA into a one liter volumetric flask. Dissolve with 950 mL water. Add 50 ml_ acetonitrile and mix well. Tigecycline Reference Standard - Of known strength (S).
• RRT is the relative retention (in column chromatography) : ratio of the net retention volume(time) of a component relative to a standard under identical conditions.
• KJ BRL means below reporting limit (meaning less than 0.05% of tigecycline peak).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Dermatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (2)

Family

ID=37111782

Family Applications (1)

Country Status (22)

Cited By (3)

Families Citing this family (17)

Family Cites Families (9)

• 2006
  • 2006-06-15 PE PE2006000670A patent/PE20070072A1/es not_active Application Discontinuation
  • 2006-06-15 AR ARP060102533A patent/AR055336A1/es unknown
  • 2006-06-16 KR KR1020087001124A patent/KR20080024201A/ko not_active Withdrawn
  • 2006-06-16 WO PCT/US2006/023613 patent/WO2006138641A2/en not_active Ceased
  • 2006-06-16 JP JP2008517178A patent/JP2008543871A/ja active Pending
  • 2006-06-16 SV SV2006002575A patent/SV2007002575A/es unknown
  • 2006-06-16 BR BRPI0612228-0A patent/BRPI0612228A2/pt not_active IP Right Cessation
  • 2006-06-16 AU AU2006261636A patent/AU2006261636A1/en not_active Abandoned
  • 2006-06-16 CN CNA2006800213849A patent/CN101198315A/zh active Pending
  • 2006-06-16 PA PA20068680201A patent/PA8680201A1/es unknown
  • 2006-06-16 EP EP06773424A patent/EP1898884A2/en not_active Withdrawn
  • 2006-06-16 RU RU2007145595/15A patent/RU2007145595A/ru not_active Application Discontinuation
  • 2006-06-16 MX MX2007015960A patent/MX2007015960A/es unknown
  • 2006-06-16 CA CA002610909A patent/CA2610909A1/en not_active Abandoned
  • 2006-06-16 US US11/455,144 patent/US7705168B2/en not_active Expired - Fee Related
  • 2006-06-16 TW TW095121834A patent/TW200716203A/zh unknown
  • 2006-06-16 GT GT200600259A patent/GT200600259A/es unknown
• 2007
  • 2007-12-05 NO NO20076264A patent/NO20076264L/no not_active Application Discontinuation
  • 2007-12-06 IL IL187979A patent/IL187979A0/en unknown
  • 2007-12-12 EC EC2007008005A patent/ECSP078005A/es unknown
  • 2007-12-14 CR CR9594A patent/CR9594A/es unknown
  • 2007-12-14 ZA ZA200710906A patent/ZA200710906B/xx unknown
• 2009
  • 2009-06-05 JP JP2009136753A patent/JP2009191083A/ja not_active Withdrawn
  • 2009-11-05 JP JP2009254475A patent/JP2010024252A/ja not_active Withdrawn

Also Published As

Similar Documents

Legal Events